Human immunodeficiency virus influenza vaccine

The trivalent inactivated influenza vaccine can be administered to all age groups and risk populations. It is recommended that the vaccine be administered yearly to children older than 6 months of age at risk for complications from influenza, such as those with asthma, cardiac disease, sickle cell disease, human immunodeficiency virus (HIV) infection, diabetes, and other conditions that compromise respiratory function. Healthy children 6 to 23 months of age should be vaccinated because of the increased risk for influenza-related... 

Various bacterial vectors have been used to express a number of bacterial B. pertussis, S. pneumoniae, Y. pestis, and L. monocytogenes), viral (herpesvirus, influenza virus, human immunodeficiency virus, simian immunodeficiency virus, and hepatitis B virus), and parasitic (5. mansoni, and L. major) antigens. Significant improvements in attenuation of bacteria, and the stability, localization, and expression levels of heterologous antigens are required to market the bacterial vector-based vaccines for use in humans or animals. 

O Brien WA> Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang HJ, Park J, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995 86 1082 9. 

Influenza vaccine. Influenza vaccine is recommended annually for children age >6 months with certain risk factors (including but not limited to children with asthma, cardiac disease, sickle cell disease, human immunodeficiency virus infection, and diabetes and household members of persons in high-risk groups [see MMlV/ 2003 52(RR-8) 1-36j) and can be administered to all others wishing to obtain immunity. In addition, healthy children age 6 to 23 months are encouraged to receive influenza vaccine if feasible, because children in this age group are at substantially increased risk of influenza-related hospitalizations. Eor healthy persons age 5 to... 

Nelson KE, Clements ML, Miotti P, Cohn S, Polk BE. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988 109 383-388. 

---